ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 22 of 3982 for:    Recruiting, Not yet recruiting, Available Studies | "Communicable Diseases"

Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03308253
Recruitment Status : Not yet recruiting
First Posted : October 12, 2017
Last Update Posted : April 9, 2018
Sponsor:
Information provided by (Responsible Party):
McMaster University

Brief Summary:
The CDC quotes a rate of wound infection of 2-5% for inpatient surgery. Patients undergoing a vascular operation, however, are generally at an increased risk of wound infection with rates often close to 5-10%. Groin incisions are an additional risk factor for surgical site infections, with rates of wound infection being quoted from 10-15%, and even as high as 30% in high risk patients. The use of implantable calcium sulfate beads mixed with antibiotics may help to lower the rate of infection in these high risk patients.

Condition or disease Intervention/treatment Phase
Surgical Site Infection Device: Stimulan Rapid Cure Drug: Vancomycin Drug: Tobramycin Other: Standard of Care Phase 4

Detailed Description:

The initial pilot will consist of 30 patients per arm and will provide estimates of effect size, event rates, and recruitment rates. It will mirror the final study in terms of methodology. This will occur at the Hamilton General Hospital (Hamilton, ON. Canada)

Patients will be randomized to either the exposure group or control group by the study coordinator. Patients will be block randomized among surgeons (6), so that each surgeon has an equal number of patients in the control and exposure arms. Randomization will occur once an operative date has been booked for a patient. The arm they are assigned to will be how the patient is treated, regardless of if they are cancelled and re-booked. Should patients be done as an emergency procedure, prior to their index procedure (when the beads would be implanted), they will be excluded from the study. As no intervention has occurred at this point, there will be no informative loss to follow-up or censoring and therefore this will not impact validity of the design. We are unable to provide beads for emergency procedures, as the research pharmacy is not open.

The research coordinator will inform the research pharmacy to produce calcium sulfate beads impregnated with Vancomycin (1g) and Tobramycin (240mg) for the exposure arm. The control arm will receive standard care. The only difference between standard care and the treatment arm is the use of the antibiotic calcium sulfate beads. Beads will be delivered in a sterile manner to the OR. For each patient half of a standard 10cc kit will be delivered (5cc of Stimulan Calcium Sulfate). As the beads are being applied only to a groin incision(s) this will provide an adequate volume of beads. It will also prevent insertion of excess beads.

Surgeons will insert the beads loosely within the soft tissue of groin incisions, so as not to distort the normal anatomy. This technique will be discussed with all surgeons prior to pilot initiation as a group. This will aim to standardize the method among involved surgeons. At the end of the study we will complete a focus group with surgeons to discuss their experience using the beads to better inform the protocol for the final RCT. Patients are randomized as a unit and therefore, if there are bilateral groin incisions, both will be treated as per their randomization.

Patients will be blinded to which treatment they receive. The beads are believed to be non-detectable to the patient. Only by means of wound dehiscence would a patient be expected to determine their treatment group. For practical reasons the surgeon cannot be blinded to treatment. Nurse assessors and study authors conducting review of patient records will be blinded to patient treatment.

Patients will be recruited from all patients consented for an included procedure at HGH. A study coordinator or a resident will obtain consent. The patient's primary physician will not be involved in the consent process.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Pilot Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection in Vascular Surgery Patients
Estimated Study Start Date : May 2018
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics Calcium

Arm Intervention/treatment
Standard of Care
Patients will receive the standard of care for vascular procedures as it is provided at Hamilton General Hospital
Other: Standard of Care
Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.

Experimental: Antibiotic Impregnated Beads
Patients will have their wound packed with calcium sulfate beads prior to closing. The beads will be infused with the antibiotics vancomycin and tobramycin.
Device: Stimulan Rapid Cure
Calcium sulfate dissolvable beads

Drug: Vancomycin
0.5 g Vancomycin per patient

Drug: Tobramycin
120 mg tobramycin per patient




Primary Outcome Measures :
  1. Surgical Site Infection [ Time Frame: 30 days ]
    The primary outcome will be combined, superficial, deep or organ/space infection as defined by the CDC. The CDC definition for surgical site infection is one of the most widely used and is both the NSQUIP and NHSN definition.


Secondary Outcome Measures :
  1. Wound Complication Rate [ Time Frame: 30 day ]
    Wound complications will be defined as: wound dehiscence, skin edge necrosis, hematoma, seroma, increased wound exudate, graft exposure. These will be measured with a standardized form, by the blinded nurse assessor, at each follow-up appointment. They will additionally be assessed by the author reviewing patient records at thirty days. If imaging is required for diagnosis of hematoma or seroma, the result will be collected from the imaging records, and treated as consistent with the conclusions of the formal imaging report.

  2. Surgical Graft Infection Rate [ Time Frame: 90 day ]
    Graft infection is defined as; diagnosis by surgeon or surgical designate requiring re-operation or prolonged course of antibiotic therapy. An author blinded to patient treatment will review the records of the patient including patient charts, antibiotic prescriptions, home care and ID referrals and record the information in a standardized form for this endpoint.

  3. Bacterial Resistance [ Time Frame: 30 day ]
    In the event of infection requiring laboratory samples, screening for resistant bacteria will be performed. Bacterial cultures will be performed in order to determine the presence of tobramycin or vancomycin resistant strains.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women aged > 18
  • Undergoing a revascularization procedure involving the femoral artery and requiring either unilateral or bilateral groin incision
  • BMI > 30
  • Presence of one of the following: current smoker, diabetes requiring pharmacologic intervention, previous re-vascularization procedure

Exclusion Criteria:

  • Any patient with a current infection or requiring ongoing use of antibiotics
  • Any patient who otherwise has an indication requiring the use of antibiotic impregnated material
  • Known allergy or sensitivity to tobramycin or vancomycin
  • Grade 4 or 5 chronic kidney disease
  • Moderate or severe hypercalcemia
  • Any woman currently pregnant or planning on becoming pregnant during the course of the study
  • Any patient involved in another study that, in the investigators opinion, is believed will interfere with the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03308253


Contacts
Contact: Steven Phillips, MSc 905-521-2100 ext 44167 phills3@mcmaster.ca

Sponsors and Collaborators
McMaster University
Investigators
Principal Investigator: Michael C Stacey, DS McMaster University

Responsible Party: McMaster University
ClinicalTrials.gov Identifier: NCT03308253     History of Changes
Other Study ID Numbers: Antimicrobial Beads
First Posted: October 12, 2017    Key Record Dates
Last Update Posted: April 9, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Individual patient data will not be shared for this pilot study.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by McMaster University:
Vascular Surgery
Surgical Site Infection
Prophylactic Antibiotics
Implantable Beads

Additional relevant MeSH terms:
Infection
Communicable Diseases
Surgical Wound Infection
Wound Infection
Postoperative Complications
Pathologic Processes
Anti-Bacterial Agents
Vancomycin
Tobramycin
Antibiotics, Antitubercular
Calcium, Dietary
Anti-Infective Agents
Antitubercular Agents
Bone Density Conservation Agents
Physiological Effects of Drugs